IBDEI1D0 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24084,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24084,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,24084,1,2,0)
 ;;=2^LYMPHOMA,MANTLE CELL,UNSPEC
 ;;^UTILITY(U,$J,358.3,24084,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,24085,0)
 ;;=200.30^^133^1468^33
 ;;^UTILITY(U,$J,358.3,24085,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24085,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,24085,1,2,0)
 ;;=2^LYMPHOMA,MARGINAL ZONE,UNSPEC
 ;;^UTILITY(U,$J,358.3,24085,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,24086,0)
 ;;=200.50^^133^1468^35
 ;;^UTILITY(U,$J,358.3,24086,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24086,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,24086,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS,UNSPEC
 ;;^UTILITY(U,$J,358.3,24086,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,24087,0)
 ;;=202.90^^133^1468^34
 ;;^UTILITY(U,$J,358.3,24087,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24087,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,24087,1,2,0)
 ;;=2^LYMPHOMA,OTH SITE,UNSPEC
 ;;^UTILITY(U,$J,358.3,24087,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,24088,0)
 ;;=200.10^^133^1468^36
 ;;^UTILITY(U,$J,358.3,24088,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24088,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,24088,1,2,0)
 ;;=2^LYMPHOSARCOMA,UNSPEC
 ;;^UTILITY(U,$J,358.3,24088,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,24089,0)
 ;;=172.9^^133^1468^40
 ;;^UTILITY(U,$J,358.3,24089,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24089,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,24089,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,24089,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,24090,0)
 ;;=199.0^^133^1468^16
 ;;^UTILITY(U,$J,358.3,24090,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24090,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,24090,1,2,0)
 ;;=2^DISSEMINATED CANCER
 ;;^UTILITY(U,$J,358.3,24090,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,24091,0)
 ;;=203.00^^133^1468^44
 ;;^UTILITY(U,$J,358.3,24091,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24091,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,24091,1,2,0)
 ;;=2^MULTIPLE MYELOMA w/o REM
 ;;^UTILITY(U,$J,358.3,24091,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,24092,0)
 ;;=238.75^^133^1468^45
 ;;^UTILITY(U,$J,358.3,24092,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24092,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,24092,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME,UNSPEC
 ;;^UTILITY(U,$J,358.3,24092,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,24093,0)
 ;;=157.9^^133^1468^47
 ;;^UTILITY(U,$J,358.3,24093,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24093,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,24093,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,24093,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,24094,0)
 ;;=187.9^^133^1468^48
 ;;^UTILITY(U,$J,358.3,24094,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24094,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,24094,1,2,0)
 ;;=2^PENILE CANCER,UNSPEC
 ;;^UTILITY(U,$J,358.3,24094,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,24095,0)
 ;;=163.9^^133^1468^50
 ;;^UTILITY(U,$J,358.3,24095,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24095,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,24095,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,24095,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,24096,0)
 ;;=185.^^133^1468^51
 ;;^UTILITY(U,$J,358.3,24096,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24096,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,24096,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,24096,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,24097,0)
 ;;=287.9^^133^1468^52
 ;;^UTILITY(U,$J,358.3,24097,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24097,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,24097,1,2,0)
 ;;=2^PURPURA/OTH HEMORRHAGIC COND
 ;;
 ;;$END ROU IBDEI1D0
